Federal Register / Vol. 78, No. 6 / Wednesday, January 9, 2013 / Notices 1863 

Independent Container Line Ltd.; 

Kawasaki Kisen Kaisha, Ltd.; Nippon 

Yusen Kaisha; Norasia Container Lines 

Limited; Safmarine Container Lines 

N.V.; United Arab Shipping Company 

(S.A.G.); Wallenius Wilhelmsen 

Logistics AS; YangMing Marine 

Transport Corp.; Zim Integrated 

Shipping Services, Ltd. 

Filing Party: Wayne R. Rohde, Esq.; 

Cozen O’Connor; 1627 I Street NW., 

Suite 1100; Washington, DC 20006. 

Synopsis: The amendment removes 

Hoegh Autoliners A/S. as party to the 

Agreement. 

Agreement No.: 012128–002. 

Title: Southern Africa Agreement. 

Parties: A.P. Moller-Maersk A/S 

trading under the name Maersk Line, 

and Mediterranean Shipping Company 

S.A. 

Filing Party: Wayne R. Rohde, 

Esquire; Cozen O’Connor; 1627 I Street 

NW., Suite 1100; Washington, DC 

20006–4007. 

Synopsis: The amendment deletes 

Safmarine Container Lines N.V. as a 

party to the agreement and makes the 

corresponding technical corrections 

necessary to reflect the fact that the 

agreement has only two parties. 

By Order of the Federal Maritime 

Commission. 

Dated: January 4, 2013. 

Karen V. Gregory, 

Secretary. 

[FR Doc. 2013–00274 Filed 1–8–13; 8:45 am] 

BILLING CODE 6730–01–P 

FEDERAL MARITIME COMMISSION 

Ocean Transportation Intermediary 

License Applicants 

The Commission gives notice that the 

following applicants have filed an 

application for an Ocean Transportation 

Intermediary (OTI) license as a NonVessel-Operating Common Carrier 

(NVO) and/or Ocean Freight Forwarder 

(OFF) pursuant to section 19 of the 

Shipping Act of 1984 (46 U.S.C. 40101). 

Notice is also given of the filing of 

applications to amend an existing OTI 

license or the Qualifying Individual (QI) 

for a licensee. 

Interested persons may contact the 

Office of Ocean Transportation 

Intermediaries, Federal Maritime 

Commission, Washington, DC 20573, by 

telephone at (202) 523–5843 or by email 

at OTI@fmc.gov. 

Best Global Logistics USA, Inc. dba 

Siam Intercargo Services (NVO & 

OFF), 1207 West Mahalo Place, Suite 

100, Compton, CA 90220, Officers: 

Tai-Chuen (Larry) Che, Vice President 

(QI), Wing-Ham Chu, Director, 

Application Type: Delete Trade Name 

Siam Intercargo Services/QI Change. 

Carmichael International Service dba 

C.I. Container Line (NVO & OFF), 533 

Glendale Blvd., Los Angeles, CA 

90026, Officers: John Salvo, CoPresident (QI), Vincent Salvo, CoPresident, Application Type: QI 

Change. 

OTA America, Inc. (NVO & OFF), 927 

Teak Street, Brea, CA 92821, Officers: 

Dookee Kim, Secretary (QI), 

Kyoungmi Lee, CEO, Application 

Type: New NVO & OFF License. 

Salmad Ocean Line & Logistics, Inc. 

(NVO & OFF), 4854 Old National 

Hwy., Suite 205, College Park, GA 

30337, Officer: Amadu K. Jah, 

President (QI), Application Type: 

Name Change to Sea Freight Express, 

Inc. 

Watercraft Mix, Inc. (NVO & OFF), 4380 

E. 11th Avenue, Hialeah, FL 33013, 

Officer: Dmitry Poyarkov, President 

(QI), 

Application Type: QI Change. 

By the Commission. 

Dated: January 4, 2013. 

Karen V. Gregory, 

Secretary. 

[FR Doc. 2013–00273 Filed 1–8–13; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, 

Chemosensory Fellowships Review Meeting. 

Date: February 22, 2013. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Kausik Ray, Ph.D., 

Scientific Review Officer, National Institute 

on Deafness and Other Communication 

Disorders, National Institutes of Health, 

Rockville, MD 20850, 301–402–3587, 

rayk@nidcd.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special, Emphasis Panel, NIDCD 

P30 Review Meeting. 

Date: March 8, 2013. 

Time: 8:00 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Kausik Ray, Ph.D., 

Scientific Review Officer, National Institute 

on Deafness and Other Communication 

Disorders, National Institutes of Health, 

Rockville, MD 20850, 301–402–3587, 

rayk@nidcd.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: January 3, 2013. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2013–00176 Filed 1–8–13; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, Middle 

Ear P50 Review. 

Date: February 8, 2013. 

Time: 4:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


srobinson on DSK4SPTVN1PROD with 
1864 Federal Register / Vol. 78, No. 6 / Wednesday, January 9, 2013 / Notices 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Christine A. Livingston, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institutes of 

Health/NIDCD, 6120 Executive Blvd.—MSC 

7180, Bethesda, MD 20892, (301) 496–8683, 

livingsc@mail.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, Chemical 

Senses Clinical Trial Review. 

Date: February 28, 2013. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852. 

Contact Person: Christine A. Livingston, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institutes of 

Health/NIDCD, 6120 Executive Blvd.—MSC 

7180, Bethesda, MD 20892, (301) 496–8683, 

livingsc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: January 3, 2013. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2013–00175 Filed 1–8–13; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Phase II Trials in Lung Disease. 

Date: February 1, 2013. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Renaissance Washington DC, 

Dupont Circle, 1143 New Hampshire Avenue 

NW., Washington, DC 20037. 

Contact Person: Stephanie L. Constant, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7189, Bethesda, MD 20892, 301– 

443–8784, constantsl@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: January 3, 2013. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2013–00172 Filed 1–8–13; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group, 

Pregnancy and Neonatology Study Section. 

Date: February 5–6, 2013. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Michael Knecht, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6176, 

MSC 7892, Bethesda, MD 20892, (301) 435– 

1046, knechtm@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group, Sensorimotor 

Integration Study Section. 

Date: February 8, 2013. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Delfina Santa Monica 

Hotel, 530 West Pico Boulevard, Santa 

Monica, CA 90405. 

Contact Person: John Bishop, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892, (301) 408– 

9664, bishopj@csr.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group, 

Dissemination and Implementation Research 

in Health Study Section. 

Date: February 8, 2013. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Jacinta Bronte-Tinkew, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3164, 

MSC 7770, Bethesda, MD 20892, (301) 806– 

0009, brontetinkewjm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RFA Panel: 

System Science and Health in the Behavioral 

and Social Sciences. 

Date: February 8, 2013. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Inner Harbor, 301 W. 

Lombard Street, Baltimore, MD 21201. 

Contact Person: Tomas Drgon, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3152, 

MSC 7770, Bethesda, MD 20892, 301–435– 

1017, tdrgon@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cancer 

Therapeutics Area Grant Application. 

Date: February 8, 2013. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Dupont Circle Hotel, 1500 New 

Hampshire Avenue NW., Washington, DC 

20036. 

Contact Person: Denise R. Shaw, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6158, 

MSC 7804, Bethesda, MD 20892, 301–435– 

0198, shawdeni@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR–10– 

018 Accelerating the Pace of Drug Abuse 

Research Using Existing Epidemiology, 

Prevention, and Treatment Research Data. 

Date: February 8, 2013. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: George Vogler, Ph.D., 

Scientific Review Officer, PSE IRG, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3140, 

Bethesda, MD 20892, 301–435–0694, 

voglergp@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR 11– 


srobinson on DSK4SPTVN1PROD with